Polar Capital Reports 5.58% Of Savara As Its Only Clinical Program Awaits FDA Decision

The two reporting entities listed the same 11,456,114 shares, with the lung-disease drug's regulatory decision scheduled for Sunday.

Share
Polar Capital Reports 5.58% Of Savara As Its Only Clinical Program Awaits FDA Decision

Polar Capital reported a 5.58% stake in Savara, which develops medicines for rare respiratory diseases, in a passive ownership disclosure filed Monday. The holding was measured as of September 30, while Savara's only clinical program, Molbreevi, awaits an FDA decision scheduled for Sunday.

One Holding, Two Reporting Entities

Polar Capital Holdings and Polar Capital LLP, the investment adviser reporting alongside the holding company, each listed 11,456,114 shares. Both reported sole voting authority over that holding; the two entries describe the same position.

The stake's percentage uses 205,460,015 outstanding shares, the count Savara reported in its quarterly filing on August 11. The firms certified that they bought and hold the securities in the course of ordinary business, without seeking to change or influence control of Savara.

Molbreevi's Approval Wait

Molbreevi's late-stage Impala-2 trial met its goal: patients showed a statistically significant improvement in the lungs' ability to move gases into the bloodstream after 24 weeks. The FDA granted priority review but moved its target decision from August to November 22.

Savara said in its Thursday announcement that the treatment is not yet approved for any indication. The pending decision concerns the company's sole clinical program.

The medicine, also called molgramostim inhalation solution or MOLBREEVI, targets autoimmune pulmonary alveolar proteinosis. The rare disease causes fatty, protein-rich material to accumulate in the lungs' air sacs, making breathing difficult.

Patients inhale the investigational treatment through PARI's eFlow nebulizer, which converts liquid medicine into mist. Savara holds worldwide rights and contracts out manufacturing and most clinical development work.

Impala-2 finished enrollment in June 2023 with 164 patients. Savara's expanded access program takes physician requests for eligible patients in selected North American and European countries.

The FDA's target decision Sunday puts Molbreevi's approval next on Savara's calendar.

Sources